{"id":666827,"date":"2025-12-17T17:16:04","date_gmt":"2025-12-17T17:16:04","guid":{"rendered":"https:\/\/microscopemedia.com\/?p=666827"},"modified":"2025-12-17T17:16:04","modified_gmt":"2025-12-17T17:16:04","slug":"miracol-medical-oamenii-de-stiinta-au-descoperit-o-metoda-care-ar-putea-vindeca-un-tip-de-leucemie","status":"publish","type":"post","link":"https:\/\/microscopemedia.com\/?p=666827","title":{"rendered":"Miracol medical. Oamenii de \u0219tiin\u021b\u0103 au descoperit o metod\u0103 care ar putea vindeca un tip de leucemie"},"content":{"rendered":"
<\/div>\n

Studiul publicat \u00een New England Journal of Medicine marcheaz\u0103 prima utilizare uman\u0103 a celulelor CAR-T editate genetic prin tehnica de editare a bazelor ADN, oferind speran\u021b\u0103 real\u0103 pacien\u021bilor.<\/p>\n

Cum func\u021bioneaz\u0103 terapia cu celule CAR-T editate genetic<\/strong><\/h2>\n

Terapia se bazeaz\u0103 pe tehnica de editare a bazelor, o form\u0103 avansat\u0103 de CRISPR-Cas9, care permite modificarea precis\u0103 a literelor ADN f\u0103r\u0103 a t\u0103ia lan\u021bul genetic. Echipa de cercet\u0103tori a efectuat patru modific\u0103ri asupra celulelor T donatoare:<\/p>\n

    \n
  1. \n

    Eliminarea receptorului TCR pentru a preveni respingerea celulelor de c\u0103tre organism.<\/p>\n<\/li>\n

  2. \n

    \u00cenl\u0103turarea HLA (antigen uman leucocitar), transform\u00e2nd celulele \u00een \u201cuniversale\u201d \u0219i compatibile pentru orice pacient.<\/p>\n<\/li>\n

  3. \n

    \u0218tergerea proteinelor CD7 \u0219i CD52 de pe suprafa\u021ba celulelor T donatoare, astfel \u00eenc\u00e2t s\u0103 fie protejate \u00eempotriva medicamentului alemtuzumab \u0219i s\u0103 \u021binteasc\u0103 exclusiv celulele canceroase.<\/p>\n<\/li>\n

  4. \n

    Introducerea unui receptor CAR anti-CD7 care identific\u0103 \u0219i distruge celulele T-ALL.<\/p>\n<\/li>\n<\/ol>\n

    Rezultatele studiului clinic<\/strong><\/h2>\n

    Faza ini\u021bial\u0103 a studiului, desf\u0103\u0219urat\u0103 \u00een 2022 pe 11 pacien\u021bi, majoritatea copii, a \u00eenregistrat o rat\u0103 de remisie ini\u021bial\u0103 de 100%. Dintre ace\u0219tia, 82% au ajuns la remisie profund\u0103 sau nedetectabil\u0103 \u00een patru s\u0103pt\u0103m\u00e2ni, fiind eligibili pentru transplant de celule stem. Dup\u0103 tratament, aproximativ 64% dintre pacien\u021bi r\u0103m\u00e2n complet f\u0103r\u0103 boal\u0103, unii fiind vindeca\u021bi de mai bine de trei ani.<\/p>\n

    Primul pacient tratat, Alyssa, diagnosticat\u0103 la 13 ani cu T-ALL \u0219i f\u0103r\u0103 alte op\u021biuni, este \u201ecancer-free\u201d din 2022 \u0219i tr\u0103ie\u0219te o via\u021b\u0103 normal\u0103 la 16 ani.<\/p>\n

    Avantaje \u0219i perspective viitoare<\/strong><\/h2>\n

    Aceast\u0103 terapie nu doar ofer\u0103 o \u0219ans\u0103 real\u0103 pacien\u021bilor cu leucemie T-ALL considerat\u0103 incurabil\u0103, ci demonstreaz\u0103 \u0219i poten\u021bialul celulelor universale s\u0103 accelereze \u0219i s\u0103 reduc\u0103 costurile tratamentului CAR-T \u00een viitor.<\/p>\n

    Printre efectele secundare se num\u0103r\u0103 reac\u021biile imunitare exagerate, erup\u021biile cutanate \u0219i sc\u0103derea temporar\u0103 a num\u0103rului de celule sanguine, dar beneficiile pe termen lung sunt promi\u021b\u0103toare.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Studiul publicat \u00een New England Journal of Medicine marcheaz\u0103 prima utilizare uman\u0103 a celulelor CAR-T editate genetic prin tehnica de editare a bazelor ADN, oferind speran\u021b\u0103 real\u0103 pacien\u021bilor. Cum func\u021bioneaz\u0103 … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":666828,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/666827"}],"collection":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=666827"}],"version-history":[{"count":0,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/666827\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/media\/666828"}],"wp:attachment":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=666827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=666827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=666827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}